Considering that JMJD3 plays a dual role in renal fibrosis, JMJD3-targeted therapies should be administered according to the type of disease in the clinical setting, and more in-depth studies are also needed to explore the mechanisms behind the differences. This evidence concerns the gene KDM6B and renal fibrosis.